SOLICITATION NOTICE
A -- Development of Antibodies and Reference Standards for Assessing Human Exposure to Cholonesterase Inhibitors
- Notice Date
- 6/9/2015
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2015-N-17157
- Archive Date
- 7/9/2015
- Point of Contact
- Tessa W Buffington, Phone: 7704882612
- E-Mail Address
-
vsr3@cdc.gov
(vsr3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC), National Center of Environmental Health, Division of Laboratory Sciences, intends to award a sole source contract to the University of Nebraska Medical Center, Eppley Institute, Department of Biochemistry and Molecular Biology, Omaha, NE 68198, for the acquisition of the effort entitled "Development of Antibodies and Reference Standards for Assessing Human Exposure to Cholinesterase Inhibitors." The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1 - only one responsible source and no other supplies or services will satisfy the agency requirements. The NAICS code for this procurement is 611310, Colleges, Universities, and Professional Schools. The period of performance for this procurement is twelve (12) months. The purpose of this acquisition is to develop monoclonal antibodies and reference standard proteins specific for measuring long-term protein biomarkers of exposure to cholinesterase inhibitors in clinical samples. For this project, monoclonal antibodies which are specific for binding denatured butyrylcholinesterase and organophosphate adducted tyrosine will be developed, identified, and tested for potential inclusion in CDC clinical assays for confirming exposure to cholinesterase inhibitors. Incorporation of these antibodies will enhance sensitivity, specificity, and time post exposure for analysis for CDC's emergency response methods. Following this review, a final set of candidate antibodies will be prepared and all information on clinical significance, proper sample processing and handling, and how to incorporate the new antibodies into CDC's current mass spectronomy based methods will be transferred to CDC in the form of written reports by the contractor. Additionally, limited amounts of purified active native/recombinant cholinesterase standards will also be provided for incorporation into clinical assays. The University of Nebraska Medical Center is the only responsible source capable of meeting all of the Government's requirements. UNMC has access to human clinical samples including serum/plasma and whole blood inhibited by organphosphorus compounds including nerve agents, jet engine lubricant additives, and organophosphorus pesticides; such access to samples is an absolute requirement for developing the monoclonal antibodies needed in this requirement. The lab is a respected, international leader in the field of cholinesterates and has a proven track record for developing new monoclonal antibodies of this nature. This lab also has a proven track record of demonstrating their ability to generate large amounts of native, highly purified cholinesterase inhibitor biomarker proteins and is the world leader in large scale purification of native butyrylcholinesterase that retains enzymatic activity from clinical samples. Such skills are a necessity for antibody development and screening in this project. Additionally, this laboratory has years of experience maintaining viability of monoclonal antibody producing hybridoma cell lines in the long term which is critical for this work. This laboratory is the only one capable of testing any new monoclonal antibodies that are developed using the same immunomagnetic separation (IMS) liquid chromotography-tandem mass spectronomy (LC-MS/MS) approach that is used in CDC's clinical assays for assessing exposure to OPNAs. The requirements associated with the research and development needs for the development of monoclonal antibodies and reference proteins specific for long term biomarkers of exposure to OPNA's for incorporation into CDC's suite of emergency response methods are unique, and the proposed work is a follow on to work completed under CDC contracts 200-2012-M-53381 and 200-2013-57169. Due to the concerns for continuity of the project, as well as being the primary contributor to monoclnal antibody development in this field, the University of Nebraska Medical Center is the only resource that satisfied all the requirements of this request. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to The University of Nebraska Medical Center. However, all responsible sources that believe they can meet these requirements may submit a capabilities statement to provide the services to Tessa Buffington via email ONLY at vsr3@cdc.gov with the solicitation number 2015-N-17157 referenced in the subject line NO LATER THAN June 24, 2015. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2015-N-17157/listing.html)
- Place of Performance
- Address: University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, Nebraska, 68198, United States
- Zip Code: 68198
- Zip Code: 68198
- Record
- SN03758119-W 20150611/150609235323-7d45f3c89f6d41532af371e84c9bb211 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |